{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:07Z","timestamp":1783521667774,"version":"3.55.0"},"reference-count":44,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Malignant peritoneal mesothelioma is a rare malignancy arising from the serosa of the peritoneal cavity. It is diagnosed based on suspicious findings on cross sectional imaging and a tissue biopsy showing confirmatory histologic and immunohistochemical features. The disease is hallmarked by its propensity to progress mainly in the peritoneal cavity. In selected patients, surgical cytoreduction and hyperthermic intra-operative peritoneal chemotherapy has become the initial preferred treatment and is associated with provide prolonged in many patients. Systemic chemotherapy using a couplet of cisplatin or gemcitabine with pemetrexed has modest response rates and duration of response. Expression of PD-L1 has been demonstrated in peritoneal mesothelioma tumors and there has been significant interest in the use of check point blockade targeted against PD-L1 in this clinical setting. Future clinical research using a combination of check point blockade with surgical cytoreduction is a high clinical priority.<\/jats:p>","DOI":"10.3390\/jcm11071891","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:44:52Z","timestamp":1648590292000},"page":"1891","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Patients with Malignant Peritoneal Mesothelioma"],"prefix":"10.3390","volume":"11","author":[{"given":"Claire Y.","family":"Li","sequence":"first","affiliation":[{"name":"Department of Surgery, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0687-9434","authenticated-orcid":false,"given":"Henry Richard","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/path.1700120212","article-title":"Malignant tumor arising from endothelium of peritoneum, and producing mucoid ascitic fluid","volume":"12","author":"Miller","year":"1908","journal-title":"J. Path. Bact."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1097-0142(196001\/02)13:1<127::AID-CNCR2820130124>3.0.CO;2-6","article-title":"Malignant peritoneal mesotheliomas.A clinicopathological analysis of 12 fatal cases","volume":"13","author":"Winslow","year":"1960","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1001\/jama.1964.03060270028006","article-title":"Asbestos Exposure and Neoplasia","volume":"188","author":"Selikoff","year":"1964","journal-title":"JAMA J. Am. Med Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(19)33323-2","article-title":"Peritoneal mesothelioma","volume":"63","author":"Moertel","year":"1972","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.1983.1.6.386","article-title":"Peritoneal mesothelioma: \tNatural history and response to chemotherapy","volume":"1","author":"Antman","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1245\/s10434-019-08138-5","article-title":"Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: An Analysis of 2000 Patients from the National Cancer Database","volume":"27","author":"Bijelic","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","article-title":"Current Trends in the Management of Malignant Peritoneal Mesothelioma","volume":"21","author":"Miura","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff","year":"1980","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 Is Altered by Copy Number Loss, Mutation, and\/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington Cancer Institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_13","first-page":"343","article-title":"Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma","volume":"134","author":"Alexander","year":"2007","journal-title":"Cancer Treat Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.20836","article-title":"Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy","volume":"103","author":"Yan","year":"2005","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","article-title":"A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival","volume":"20","author":"Schaub","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdl060","article-title":"Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference","volume":"17","author":"Hassan","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis","volume":"22","author":"Helm","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","article-title":"Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"24","author":"Li","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-018-1125-4","article-title":"The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking","volume":"35","author":"Naffouje","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1245\/s10434-007-9701-4","article-title":"Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center","volume":"15","author":"Gusani","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: Correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","article-title":"Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study","volume":"19","author":"Baratti","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1245\/s10434-020-09232-9","article-title":"CRS\/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative","volume":"27","author":"Roife","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1245\/s10434-019-08141-w","article-title":"The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis","volume":"27","author":"Bekhor","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","article-title":"Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome","volume":"22","author":"Ihemelandu","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11605-021-05084-0","article-title":"Survival Outcomes for Malignant Peritoneal Mesothelioma at Academic Versus Community Hospitals","volume":"26","author":"Welten","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","article-title":"Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin","volume":"17","author":"Blackham","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1245\/s10434-021-11060-4","article-title":"ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study","volume":"29","author":"Kepenekian","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program","volume":"7","author":"Wozniak","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial","volume":"26","author":"Simon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e026779","DOI":"10.1136\/bmjopen-2018-026779","article-title":"Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC trial","volume":"9","author":"Burger","year":"2019","journal-title":"BMJ Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1891\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:45:28Z","timestamp":1760136328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11071891"],"URL":"https:\/\/doi.org\/10.3390\/jcm11071891","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}